Continuing Education Webinars - On Demand

Myriad Oncology hosts educational content for Nurses and Genetic Counselors throughout the year. These continuing education opportunities have been recorded and can be viewed at your convenience. Listed below are the recorded webinars in the Evolving Strategies in Hereditary Cancer series.

Optional continuing education contact hours can be received if the survey is completed after watching the video.

Please view each individual video for updated instructions on how to receive this continuing education credit.

Evolving strategies in genetics and genomics 2024

This program provides a summary of the evolution of APC related syndromes including FAP, AFAP, and GAPPS. Our speakers will examine the phenotypic spectrum of APC mutations and genetic testing strategies to polyposis cases.

Learning Objectives:

  • Summarize the evolution of APC related syndromes including FAP, AFAP, and GAPPS.
  • Examine the phenotypic spectrum of APC mutations
  • Apply genetic testing strategies to polyposis cases

This program provides a summary of recent literature related to CHEK2-associated cancer risks and management implications. Our speakers will evaluate current evidence that compares the cancer risks associated with different types of germline CHEK2 variants.

Learning Objectives:

  • Identify challenges of CHEK2 variant classification as reviewed in recent clinical practice guidelines.
  • Define evidence for cancer risk associated with germline pathogenic variants (PV) in CHEK2
  • Examine management implications for CHEK2-associated cancer risks.
  • Summarize recent evidence comparing cancer risks between individuals with different types of germline CHEK2 variants.

This program highlights literature updates in reproductive and oncology genetics and discusses appropriate follow-up approaches for patient management.

Learning Objectives:

  • Summarize recent literature in reproductive and oncology genetics.
  • Examine universal germline testing utilization for management in breast cancer.
  • Evaluate the barriers and benefits of universal somatic and germline testing in oncology practice.
  • Identify the challenges of unexpected findings identified by reproductive genetic screening.
  • Illustrate how imaging can play a critical role following identification of unexpected results in prenatal cell-free DNA screening

Evolving strategies in hereditary cancer 2023

This program will highlight the risk and management associated with hereditary polyposis genes beyond APC and discuss current literature and emerging data surrounding this syndrome.

Learning Objectives:

  • Characterize the clinical presentation and cancer risks associated with hereditary polyposis genes.
  • Outline updated hereditary polyposis management guidelines.
  • Examine current literature and emerging data surrounding genes associated with polyposis.
  • Illustrate the diversity in clinical presentation and penetrance of hereditary polyposis using patient case examples.

This program highlights unique scenarios in interpreting germline TP53 variants and discusses appropriate follow-up approaches for patient management.

Learning Objectives:

  • Summarize the current limitations and challenges of interpreting germline results with TP53 variants.
  • Examine follow-up approaches for patients with TP53 variants found on germline testing.
  • Construct a plan for continued follow-up for patients with TP53 variants.

This program details the initiatives of the Cancer Moonshot program and discusses evolving guidelines of high-risk management for patients with hereditary cancer syndromes and cancer survivors..

Learning Objectives:

  • Evaluate unique Approaches to Identify and Care for Individuals with Inherited Cancer Syndromes including the evolution of the Cancer Moonshot initiatives.
  • Illustrate Communication and Decision-Making for Individuals with Inherited Cancer Syndromes.
  • Examine Strategies to Optimize Management and Outcomes for Cancer Survivors in a high-risk clinic.
  • Identify Lifestyle Risk Factors and Methods to Reduce Cancer Risks.

This program examines breast cancer genes beyond BRCA 1 and BRCA 2 and will focus on risk and medical management associated with these mutations.
Learning Objectives:

  • Examine current literature and emerging data surrounding hereditary breast cancer risk assessment and testing.
  • Characterize the clinical presentation and cancer risks associated with breast cancer genes outside of BRCA1/2.
  • Outline updated management and risk reduction strategies for carriers of mutations in moderate penetrance breast cancer genes.

This program will examine somatic and germline testing in clinical oncology settings and focus on differentiation and clinical application of genomic tests to improve patient care and outcomes.

  1. Summarize information related to germline and somatic genetic testing.
  2. Evaluate the utility of somatic and germline tests within the clinical genetic setting.
  3. Illustrate the overlap of cancer genetic counseling and surgical/oncology treatment discussions related to germline and somatic results.
  4. Examine strategies to review tumor-only testing for potential germline findings

This program will examine implicit bias within healthcare and discuss its impact on the providers and patients while introducing strategies for equitable care to improve patient outcomes.

Learning Objectives

  1. Evaluate how barriers lead to variability in breast cancer management.
  2. Identify strategies to improve equity in cancer care.
  3. Deconstruct implicit bias and its impact on oncology care.

Evolving strategies in hereditary cancer 2022

This program will evaluate various risk assessment methods and focus on risk reducing therapies for patients with an increased risk of breast cancer.

Learning Objectives

  1. Evaluate current breast cancer risk assessment methods including germline genetics, polygenic risk scores, and risk modeling.
  2. Examine an evidence-based overview of endocrine therapy for breast cancer prevention.
  3. Summarize a practice approach to risk stratification and management for patients with general, moderate, and high risk of developing breast cancer.

This program will discuss risk assessment, treatment and opportunities to increase access for genetic testing for patients at risk or diagnosed with prostate cancer.

Learning Objectives

  1. Define methods in diagnosing and identifying patients with high-risk prostate cancer.
  2. Summarize pathways for prostate cancer treatment planning.
  3. Evaluate barriers to implementation of germline genetic testing for patients with prostate cancer.
  4. Identify opportunities to improve access to germline genetic testing for patients at risk for hereditary prostate cancer

This program will discuss hereditary renal tumor syndromes and highlight criteria for identifying patients at risk for hereditary renal cell carcinoma as well as discuss management for affected patients.

Learning Objectives

  • Identify patients who are at risk for hereditary renal tumor syndromes
  • Define hereditary renal tumor syndromes and related risks
  • Examine management and treatment options for patients with hereditary renal tumor syndromes

This program will highlight challenges in providing equitable care for sexual and gender minority patients and examine strategies to overcome these challenges within a clinical and research construct.

Learning Objectives

  • Review terminology and historical context through which to begin to understand sexual and gender minority (SGM) identities
  • Examine current shortcomings in the healthcare system that perpetuate health disparities in the SGM community
  • Evaluate strategies and guidelines for SGM inclusivity in clinical care and research.

Evolving strategies in hereditary cancer 2021

This webinar will highlight updates in cancer treatment associated with genomic and genetic testing and address challenges and benefits of improving clinical trial enrollment for patients with hereditary cancer.

  1. Summarize tumor BRCA mutations and their implications in treatments beyond ovarian cancer.
  2. Examine barriers to enrolling individuals with inherited mutations into clinical research.
  3. Identify resources available to address challenges in engagement and clinical trial enrollment.

This webinar will examine the American Society of Breast Surgeons (ASBrS) consensus guidelines on genetic testing for all patients with breast cancer and discuss its implications on local and systemic treatment recommendations.

  1. Summarize the American Society of Breast Surgeons’ Consensus Guideline on Genetic Testing for Hereditary Breast Cancer and discuss implications to clinical practice.
  2. Examine recent literature that supports the ASBrS Consensus Guideline on Genetic Testing for Hereditary Breast Cancer in comparison to current NCCN guidelines.

More webinars coming soon